HC Wainwright Brokers Increase Earnings Estimates for NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of NRx Pharmaceuticals in a research note issued to investors on Monday, November 25th. HC Wainwright analyst V. Bernardino now anticipates that the company will post earnings per share of ($1.75) for the year, up from their previous forecast of ($3.25). HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS and FY2025 earnings at ($0.08) EPS.

Other equities analysts have also issued research reports about the company. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. Ascendiant Capital Markets raised their price objective on NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th.

NRx Pharmaceuticals Trading Down 3.1 %

NASDAQ:NRXP opened at $1.27 on Wednesday. The company has a market capitalization of $15.35 million, a P/E ratio of -0.59 and a beta of 1.27. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The firm has a fifty day simple moving average of $1.39 and a 200-day simple moving average of $2.15.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Anson Funds Management LP purchased a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.